One and Done? How CRISPR Is Changing the Clinical Outlook for Multiple Diseases

Abstract

Get full access to this article

View all access options for this article.

References

Jinek

, Chylinski

, Fonfara

, et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science , 2012; 337: 816–821

www.afro.who.int/health-topics/sickle-cell-disease

Frangoul

, Altshuler

, Capellini

Y-S

, et al. CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia. N Engl J Med , 2021; 384:252–260

Frangoul

, Locatell

, Bhatia

, et al. Efficacy and Safety of a Single Dose of Exagamglogene Autotemcel for Severe Sickle Cell Disease. Blood , 2022; doi.org/10.1182/blood-2022-162353

Locatelli

, Lang

, Li

, et al. Efficacy and Safety of a Single Dose of Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia. Blood , 2022; doi.org/10.1182/blood-2022-166881

clinicaltrials.gov/ct2/show/NCT04774536

www.intelliatx.com/wp-content/uploads/In-vivo-CRISPR-CAS9-editing-of-KLKB1-in-patients-with-HAE_ACAAI_2022_Nov_12_vF.pdf

www.intelliatx.com/wp-content/uploads/Gillmore_NTLA-2001_ATTR_cardiomyop_AHA2022_05Nov22_vFINAL.pdf

Komor

, Kim

, Packer

, et al. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature , 2016; 533: 420–424

10.

Chiesa

, Georgiadis

, Ottaviano

et al. Tvt CAR7: Phase I Clinical Trial of Base-Edited “Universal” CAR7 T Cells for Paediatric Relapsed/Refractory T-ALL. Blood , 2022; doi.org/10.1182/blood-2022-169114